Assessing average somatic CAG repeat instability at the protein level.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
16 12 2019
Historique:
received: 04 09 2019
accepted: 18 11 2019
entrez: 18 12 2019
pubmed: 18 12 2019
medline: 6 11 2020
Statut: epublish

Résumé

Sandwich ELISA-based methods use Abs that target the expanded polyglutamine (polyQ) tract to quantify mutant huntingtin (mHTT). Using Meso Scale Discovery (MSD) assay, the mHTT signal detected with MW1 Ab correlated with polyQ length and doubled with a difference of only 7 glutamine residues between equivalent amounts of purified mHTTexon1 proteins. Similar polyQ length-dependent effects on MSD signals were confirmed using endogenous full length mHTT from brains of Huntington's disease (HD) knock-in (KI) mice. We used this avidity bias to devise a method to assess average CAG repeat instability at the protein level in a mixed population of HTT proteins present in tissues. Signal detected for average polyQ length quantification at the protein level by our method exhibited a strong correlation with average CAG repeat length at the genomic DNA level determined by PCR method in striatal tissue homogenates from Hdh

Identifiants

pubmed: 31844074
doi: 10.1038/s41598-019-55202-x
pii: 10.1038/s41598-019-55202-x
pmc: PMC6915696
doi:

Substances chimiques

Antibodies 0
Huntingtin Protein 0
Peptides 0
polyglutamine 26700-71-0
DNA 9007-49-2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

19152

Références

J Mol Biol. 2015 Jul 31;427(15):2507-2519
pubmed: 26047735
Proc Natl Acad Sci U S A. 1995 Sep 12;92(19):8710-4
pubmed: 7568002
J Med Genet. 1996 Dec;33(12):1022-6
pubmed: 9004136
J Clin Invest. 2015 May;125(5):1979-86
pubmed: 25844897
J Mol Biol. 2007 Aug 3;371(1):235-44
pubmed: 17560603
Hum Mol Genet. 1995 Aug;4(8):1365-71
pubmed: 7581375
Cell. 1993 Mar 26;72(6):971-83
pubmed: 8458085
Science. 1997 Sep 26;277(5334):1990-3
pubmed: 9302293
Nature. 1995 Nov 23;378(6555):403-6
pubmed: 7477379
J Clin Invest. 2012 Oct;122(10):3731-6
pubmed: 22996692
PLoS One. 2011;6(8):e23647
pubmed: 21897851
Hum Mol Genet. 2009 Aug 15;18(16):3039-47
pubmed: 19465745
Neurology. 1999 Jan 15;52(2):392-4
pubmed: 9932964
Cell. 2015 Jul 30;162(3):516-26
pubmed: 26232222
Neurobiol Dis. 2009 Jan;33(1):37-47
pubmed: 18930147
Genetics. 2017 Feb;205(2):503-516
pubmed: 27913616
Proc Natl Acad Sci U S A. 2013 Sep 3;110(36):14610-5
pubmed: 23898200
J Biol Chem. 2003 Oct 17;278(42):41452-61
pubmed: 12888569
J Neurosci. 1999 Feb 1;19(3):964-73
pubmed: 9920660
PLoS One. 2012;7(12):e49838
pubmed: 23284626
J Neurosci. 2001 Mar 15;21(6):1830-7
pubmed: 11245667
Clin Genet. 2004 Apr;65(4):267-77
pubmed: 15025718
Hum Mol Genet. 2003 Dec 15;12(24):3359-67
pubmed: 14570710
Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12784-9
pubmed: 11675509
Sci Rep. 2017 Jul 11;7(1):5070
pubmed: 28698602
Sci Rep. 2017 Jul 20;7(1):6082
pubmed: 28729730
Hum Mol Genet. 1999 Jan;8(1):115-22
pubmed: 9887339
Neurology. 2012 Mar 6;78(10):690-5
pubmed: 22323755
Lancet Neurol. 2017 Sep;16(9):701-711
pubmed: 28642124
Sci Rep. 2015 Jul 15;5:12166
pubmed: 26174131
Nat Genet. 1997 Dec;17(4):404-10
pubmed: 9398841
PLoS Genet. 2013 Oct;9(10):e1003930
pubmed: 24204323
Brain Res Bull. 2001 Oct-Nov 1;56(3-4):319-29
pubmed: 11719267
Hum Mol Genet. 2013 Oct 15;22(20):4215-23
pubmed: 23777629
Am J Med Genet A. 2003 Jun 15;119A(3):279-82
pubmed: 12784292
Sci Rep. 2014 Jul 07;4:5601
pubmed: 24998512
Mol Neurodegener. 2015 Apr 28;10:21
pubmed: 25928884
eNeuro. 2018 Oct 10;5(4):
pubmed: 30310861
PLoS One. 2017 Dec 22;12(12):e0189891
pubmed: 29272284
Nucleic Acids Res. 1995 Apr 25;23(8):1411-8
pubmed: 7753634
Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11634-9
pubmed: 12193654
Nat Struct Mol Biol. 2007 May;14(5):381-7
pubmed: 17450152
N Engl J Med. 2019 Jun 13;380(24):2307-2316
pubmed: 31059641
Nat Commun. 2016 Nov 09;7:13272
pubmed: 27827362
Hum Genet. 1995 Mar;95(3):270-4
pubmed: 7868117
Nat Genet. 1994 Apr;6(4):409-14
pubmed: 8054984
Sci Transl Med. 2018 Sep 12;10(458):
pubmed: 30209243
Neuron. 1995 Nov;15(5):1193-201
pubmed: 7576661
Hum Mol Genet. 2017 Apr 1;26(7):1258-1267
pubmed: 28165127
Nat Chem Biol. 2011 Oct 30;7(12):925-34
pubmed: 22037470
Biotechnol J. 2007 May;2(5):559-64
pubmed: 17373643
Hum Mol Genet. 2003 Feb 1;12(3):273-81
pubmed: 12554681
Hum Mol Genet. 2017 Oct 1;26(19):3859-3867
pubmed: 28934397
Hum Mol Genet. 2000 Oct 12;9(17):2539-44
pubmed: 11030759
BMC Syst Biol. 2010 Mar 19;4:29
pubmed: 20302627
Neuron. 2019 Mar 6;101(5):801-819
pubmed: 30844400
Hum Mol Genet. 1999 May;8(5):763-74
pubmed: 10196365
J Comp Neurol. 2003 Oct 6;465(1):11-26
pubmed: 12926013
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Sci Rep. 2017 May 2;7(1):1307
pubmed: 28465506
J Huntingtons Dis. 2017;6(4):349-361
pubmed: 29125493
Lancet Neurol. 2017 Oct;16(10):837-847
pubmed: 28920889
PLoS One. 2014 May 09;9(5):e96854
pubmed: 24816435
Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3498-503
pubmed: 14993615

Auteurs

Hubert Aviolat (H)

Department of Neurology, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Ricardo Mouro Pinto (RM)

Department of Neurology, Center for Genomic Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Elizabeth Godschall (E)

Department of Neurology, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Ryan Murtha (R)

Department of Neurology, Center for Genomic Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Hannah E Richey (HE)

Department of Neurology, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Ellen Sapp (E)

Department of Neurology, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Petr Vodicka (P)

Department of Neurology, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Research Center PIGMOD, Institute of Animal Physiology and Genetics of the Czech Academy of Sciences, Libechov, Czech Republic.

Vanessa C Wheeler (VC)

Department of Neurology, Center for Genomic Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Kimberly B Kegel-Gleason (KB)

Department of Neurology, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Marian DiFiglia (M)

Department of Neurology, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. difiglia@helix.mgh.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH